What is CVRX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.04B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CVRX?

P/E (TTM) is n/a and 52-week range is $1.50 to $11.30 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CVRX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CVRX?

The company profile lists revenue (TTM) near $61M, net income (TTM) near $-5.20B, EPS (TTM) near $-1.97 when available from the market-data feed. Figures are informational and may lag live markets.

Where is CVRx Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Minneapolis, Minnesota, US, 26.5M shares outstanding, ISIN US1266381052 when available from company profile and filing metadata.

CVRx Inc

$CVRX

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$1.58

-5.95%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 223 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The firm's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.

Employees

223

Website

www.cvrx.com/

IPO

2021-06-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)